Tumor Biology

, Volume 36, Issue 3, pp 1463–1469 | Cite as

Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts

  • Xiao-Fei Ding
  • Dong-Qing Yin
  • Qian Chen
  • Hua-Yuan Zhang
  • Jun Zhou
  • Guang Chen
Research Article


Blockade of mammalian target of rapamycin (mTOR) is a promising area in breast cancer therapy. However, in clinical trials, objective response rate with mTOR inhibitor monotherapy in breast cancer was modest. Biomarker studies designed to identify the responders of rapalogs are of increasing interest. We validated p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs. We also analyzed the correlation between rapamycin activity and p27KIP1 expression in the primary breast cancer cells and the patient-derived breast tumor xenograft models. The cells isolated from the breast tumor tissues expressing high levels of p27KIP1 were sensitive to rapamycin, whereas the cells from the tissues expressing low levels of p27KIP1 exhibited resistance to rapamycin. The correlation between p27KIP1 expression and rapamycin antitumor activity was also observed in the patient-derived breast tumor xenograft models. Moreover, we also found rapamycin significantly decreased phosphorylated p70S6K1 and phosphorylated 4EBP1 in both samples. It seemed that the different sensitivity of tumor cells to rapamycin did not owe to its different potency against mTOR activity. We further propose p27KIP1 expression level may be also a candidate predictive biomarker of rapalogs for breast cancer therapy, which requires additional clinical validation.


Breast cancer mTOR Biomarker P27KIP1 Rapamycin 



This work was supported by Zhejiang Provincial Natural Science Foundation of China (no. LY12H31001, Y2110474), National Natural Science Foundation of China (no. 81201530), and Foundation of Zhejiang Educational Committee (no. Y201121896).

Conflicts of interest



  1. 1.
    Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, et al. The oral mTOR inhibitor rad001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008;44:84–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885–97.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Martin LA, Andre F, Campone M, Bachelot T, Jerusalem G. mTOR inhibitors in advanced breast cancer: ready for prime time? Cancer Treat Rev. 2013;39:742–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Vinayak S, Carlson RW: mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park) 2013;27:38–44, 46, 48 passim.Google Scholar
  6. 6.
    Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005;23:5314–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, et al. Identification of p27/kip1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med (Berl). 2010;88:941–52.CrossRefGoogle Scholar
  13. 13.
    Chu IM, Hengst L, Slingerland JM. The CDK inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8:253–67.CrossRefPubMedGoogle Scholar
  14. 14.
    Tigli H, Buyru N, Dalay N. Molecular analysis of the p27/kip1 gene in breast cancer. Mol Diagn J Devoted Underst Hum Dis Clin Appl Mol Biol. 2005;9:17–21.Google Scholar
  15. 15.
    Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27kip1 and cyclin e, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, et al. Colorectal cancer study G: low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Cli Can Res Off J Am Assoc Cancer Res. 2009;15:5888–94.CrossRefGoogle Scholar
  17. 17.
    Oka K, Suzuki Y, Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer. 2000;88:2766–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Oshita F, Kameda Y, Nishio K, Tanaka G, Yamada K, Nomura I, et al. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep. 2000;7:491–5.PubMedGoogle Scholar
  19. 19.
    Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, et al. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27kip1 expression. Blood. 2003;101:1439–45.CrossRefPubMedGoogle Scholar
  22. 22.
    Dalvai M, Schubart K, Besson A, Matthias P. Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(kip1) expression. Cell Cycle. 2010;9:3933–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008;30:701–11.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.School of MedicineTaizhou UniversityTaizhouChina
  2. 2.Taizhou Municipal HospitalTaizhouChina
  3. 3.Taizhou HospitalTaizhouChina
  4. 4.Institute of TumorTaizhou UniversityTaizhouChina
  5. 5.School of Pharmaceutical and Chemical EngineeringTaizhou UniversityTaizhouChina

Personalised recommendations